This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Why Did Eli Lilly Stock Slide 6% Despite Strong GLP-1 Momentum?
by Ahan Chakraborty
LLY stock falls 6% after an HSBC downgrade flagged persisting U.S. pricing pressure, rising market competition and compounded tirzepatide risks, despite strong GLP-1 demand.
NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Agios Pharmaceuticals Stock Declines 23% in 6 Months: Here's Why
by Zacks Equity Research
AGIO sinks 23% as mixed phase III data for mitapivat in SCD and an FDA review delay for thalassemia dent investors' confidence in its key growth drug.
AGIOPositive Net Change ANIPNegative Net Change INDVPositive Net Change
biotechs
KROS Stock: What to Know About Rinvatercept in DMD
by Ekta Bagri
Keros advances rinvatercept in DMD with orphan status, fresh phase I data, and a planned Q2 2026 phase II start driving its near-term execution story.
SRPTNegative Net Change PTCTNegative Net Change KROSNegative Net Change
biotechs medical pharmaceuticals
KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026
by Ekta Bagri
Keros lines up 2026 catalysts with rinvatercept at the core, including a Q2 DMD phase II start and ALS regulatory plans as execution shifts into focus.
SRPTNegative Net Change PTCTNegative Net Change KROSNegative Net Change
biotechnology biotechs pharmaceuticals
BAYRY Reports Positive Data on Kidney Drug in Non-Diabetic CKD
by Zacks Equity Research
Bayer's finerenone hits key phase III goal in non-diabetic CKD, paving the way to expand Kerendia???s use as data strengthens its cardiorenal therapy role.
REGNPositive Net Change JNJPositive Net Change BAYRYNo Net Change
biotechnology biotechs medical pharmaceuticals
Mirum Completes Enrollment in Late-Stage EXPAND Study of Livmarli
by Zacks Equity Research
MIRM completes enrollment in phase III EXPAND study of Livmarli for treating additional rare cholestatic liver diseases. Top-line data due in Q4 2026.
ANIPNegative Net Change MIRMNegative Net Change PHATNegative Net Change TVTXPositive Net Change
biotechs
COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM
by Zacks Equity Research
Cogent Biosciences jumps after FDA accepts bezuclastinib NDA for treating non-advanced SM, with a decision due by Dec. 30, 2026.
ANIPNegative Net Change COGTNegative Net Change REPLNegative Net Change PHATNegative Net Change
biotechs
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data
by Zacks Equity Research
CytomX Therapeutics stock surges 44% after phase I data for Varseta-M in heavily pretreated metastatic CRC show rising response rates and strong disease control.
CTMXNegative Net Change CSTLNegative Net Change ALXOPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
AstraZeneca's Imfinzi Secures Approval for Gastric Cancer in the EU
by Zacks Equity Research
AZN wins the EU nod for Imfinzi in early gastric and GEJ cancers, backed by strong survival data and expanding its blockbuster oncology footprint.
AZNPositive Net Change ANIPNegative Net Change CSTLNegative Net Change
biotechs
SRPT Stock Up as Enrollment Begins in DMD Gene Therapy Safety Study
by Zacks Equity Research
Sarepta gains as enrollment begins in a new ENDEAVOR study cohort testing a sirolimus regimen to improve Elevidys safety in DMD patients.
RHHBYPositive Net Change SRPTNegative Net Change ARWRNegative Net Change
biotechs gene-editing gene-therapy medical pharmaceuticals